TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04869111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Health Training
Description: 1. On-line SMART - (Strategic Memory Advanced Reasoning Training) is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts.~2. Stress Solutions - provides individuals with practical tools to enhance performance, reduce stress, build resilience and improve quality of life.~3. Brain-Healthy Habits - daily reminders of habits you can track~4. BrainHQ - participants will gain temporary access to the exercise-based cognitive training of BrainHQ after completing their 3rd BrainHealth Index
Study: NCT00204061

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive management
Description: The needs-focused intervention could include psychoeducation, crisis intervention, family counselling and assistance with education or work-related difficulties, according to need. Regular psychotherapy was not permitted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Description: Daily doses could range from 50 to 800 mg, with increments of 50 mg at first step and 100 mg at further steps. As a guideline, it was suggested that the dosage be increased as long as attenuated or brief limited intermittent positive symptoms were present. The interval between such steps should be at least 14 days if brief limited symptoms were absent and the APS score had improved.
Study: NCT02497937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745
Description: GSK2798745 will be supplied as granule filled capsule with unit dose strength of 2.4 mg to be administered orally with 240 mL water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as blend filled capsule to be administered orally with 240 mL water.
Study: NCT00671801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 200 mg/m\^2 by vein over 90 minutes once every 2 weeks on days 1 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given orally at escalating doses beginning 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
Study: NCT05310435

Intervention type: DEVICE
Intervention: Single volume measurement with ESD
Description: Single volume measurement with Edema Stocking device

Intervention type: DEVICE
Intervention: Single volume measurement with WDV
Description: Single volume measurement with water displacement volumetry method

Intervention type: DEVICE
Intervention: Single circumference measurement with tape measure
Description: Single circumference measurement with tape measure

Intervention type: DEVICE
Intervention: Continuous volume measurement with ESD
Description: Continuous volume measurement with Edema Stocking device
Study: NCT04110886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542
Description: Single dose, injection, starting dose of 0.2ug escalating up to 20ug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, injection matching placebo
Study: NCT01564992

Intervention type: OTHER
Intervention: Identification of genes
Description: Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.
Study: NCT03941145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced-Exertion High-Intensity Interval Training (REHIT)
Description: REHIT is a type of Sprint Interval Training (SIT) that has been shown to be efficacious at improving maximal aerobic capacity using a minimal volume of exercise.
Study: NCT02677597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Combined With S-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Combined With Paclitaxel
Study: NCT01492192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-RGD-PET-CT and perfusion CT scans on 3 occasions
Description: Fluciclatide (GE Healthcare) (AH111585) is a small cyclic peptide containing the RGD tripeptide (figure 1), which preferentially binds with high affinity to α¬vβ3 integrins that are up-regulated in angiogenesis.~The IMP is supplied as a solution for injection, 400 MBq at the reference date and time. Participants will receive one injection of the imaging agent at this dose on 3 occasions
Study: NCT00866112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational session to promote physical activity
Description: Educational session, goal setting, self monitoring of daily engagement in physical activity

Intervention type: OTHER
Group type: OTHER
Intervention: Minimal contact
Description: Self guided education manual about adopting physical activity, self monitor daily engagement in physical activity
Study: NCT02893046

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT01337817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ariva Silver Wintergreen
Description: Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ariva Wintergreen
Description: Comparator product, a compressed dissolvable smokeless tobacco lozenge containing 2 mg nicotine administered orally as a single dose.
Study: NCT01822210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: injection by gastroscopy (100 Allergen units)
Study: NCT02382315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear of Cancer Recurrence Intervention
Description: A 6-week individual therapy intervention to address fear of cancer recurrence in male and female cancer survivors. Patients will learn tools and techniques to help manage their fears, and learn to tolerate the uncertainty associated with the possibility of their cancer recurring.
Study: NCT02797977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRA737, gemcitabine, cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRA737, gemcitabine
Study: NCT03603119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline, Midazolam
Description: 2 cc normal saline i.v. after anaesthesia induction.2 mg of injection midazolam intravenous 30 minutes prior to the end of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone, ondansetron
Description: 8mg of dexamethasone i.v. after anaesthesia induction and 4 mg of ondansetron i.v. 30 minutes prior to the end of surgery.
Study: NCT03065387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT03446040

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986258
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986258
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986258
Description: Specified dose on specified days
Study: NCT02499120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib
Description: Palbociclib will be supplied as capsules containing 75 mg, 100 mg, or 125 mg equivalents of palbociclib free base. Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab injection for IV infusion will be provided in 100 mg/50 mL, single-use vials, and 200 mg/100 mL, single-use vials. In Japan, cetuximab will be provided in 100 mg/20 mL, single-use vials. Administered, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab injection for IV infusion will be provided in 100 mg/50 mL, single-use vials, and 200 mg/100 mL, single-use vials. In Japan, cetuximab will be provided in 100 mg/20 mL, single-use vials. Administered, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for palbociclib will be indistinguishable from the palbociclib capsules and will be supplied as capsules matching in size and color the various palbociclib formulations.~Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.
Study: NCT01973426

Intervention type: DEVICE
Intervention: Isolated Orthosis for Thumb Actuation (IOTA)
Description: In this pilot study, we plan to investigate whether the IOTA can effectively facilitate the ability of participants to perform a specific set of clinically relevant tasks conducted in a clinic setting. The IOTA is a device developed at the Wyss Institute at Harvard University, in collaboration with Children's Hospital Boston, for assisting opposable thumb grasping tasks. The IOTA contains an adjustable brace fitted to the thumb and dorsum of the hand that is easy to put on and facilitates grasping motions through flexible cable-driven actuators that assist with joint abduction and extension.
Study: NCT00952315

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cyberwand
Description: Dual probe lithotrite Cyberwand will be used to remove kidney stone. Duration will be timed and documented.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stonebreaker
Description: Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lithoclast Select
Description: Lithoclast Select will be used to break up and remove the kidney stone. Duration will be timed and documented
Study: NCT02377232

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid for Colon Cancer Screening
Description: Paper decision aid describing different screening options for colon cancer

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Outreach for Colon Cancer Screening
Description: Patients overdue for colon cancer screening are contacted and outreach is performed in an effort to schedule colonoscopy
Study: NCT01377636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Description: patients will receive isoproterenol, have a BIS monitoring device and a modified isolated forearm test (no neuromuscular blockade).
Study: NCT00767598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phosphodiesterase type 5 inhibitor
Description: single oral administration of 20mg vardenafil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phosphodiesterase type 5 inhibitor
Description: single oral administration of 100mg sildenafil
Study: NCT03446040

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986258
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Specified dose on specified days
Study: NCT00977977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Infusion
Description: Drug Rituximab Infusion 2 infusions (each 1000 mg) separated by 2 weeks; repeated after 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Cyclosporine
Description: Daily therapy for 6 months (3-5 mg/kg), then tapered and discontinued
Study: NCT00767598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phosphodiesterase type 5 inhibitor
Description: single oral administration of 200mg udenafil
Study: NCT01739504

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction with Local Anesthesia
Description: Liposuction under tumescent anesthesia for adipose tissue harvesting.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra articular infusion of AD-SVF
Description: Adipose tissue is available in most patients for harvest through minimally invasive procedures such as liposuction. AD-SVF can be obtained in large quantities after processing of adipose tissue in the laboratory.~* AD-SVF to promote tissue regeneration and repair with their ability to secrete various growth factors that can modulate host tissue environment.~* Patient's AD-SVF combined with PRP are used for direct intra-articular injection after processing.
Study: NCT01941199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229 + metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229 + metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229 + metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229 + metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229 + metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229 + metformin
Study: NCT01494012

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo SBRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo FDG-PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo FDG-PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG-PET/CT
Study: NCT01719159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 25 mg rituximab is injected intrathecally via an Ommaya reservoir once a week for 3 weeks. Patients are then followed for one year.
Study: NCT02472262

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cow pea complementary food
Description: A legume-based complementary food made from cowpeas will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn soy flour
Description: Corn flour with 10% soy will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Common bean
Description: A legume-based complementary food made from common beans will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
Study: NCT04442477

Intervention type: DIETARY_SUPPLEMENT
Intervention: Enriched Protein Fractions
Description: Enriched protein fractions

Intervention type: DIETARY_SUPPLEMENT
Intervention: Protein Fraction
Description: Protein fractions
Study: NCT03960827

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EE Training
Description: Participants randomized to EE engage in four center-based EE sessions each week for 12 weeks; each session lasting roughly 1-hour with a 40-45 minute stimulus phase and the remaining time being used to warm up and cool down. Each week, two of the sessions occur on a cycle ergometer and two involve treadmill exercise (4 total sessions per week). During all sessions, the participant's heart rate is monitored to ensure they maintain exercise intensity at 70% of heart rate reserve (± 5%). Periodically during training sessions perceptual data from participants are recorded, which is used to track the subjective experience of participants and in interpreting adherence data.
Study: NCT02963636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist clinical intervention
Description: Pharmacists will make a clinical intervention with patients. They will review patient drug therapy already prescribed in their usual care. This includes a medication reconciliation, an assessment of drug related problems, an assessment of the regimen complexity and adherence to treatment. A care plan will be elaborated. Moreover, immediate and future interventions with the patient or other health professionals will be implemented and monitored. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.
Study: NCT04162795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine (Claritin, BAY76-2211)
Description: Chewable tablet, oral, single dose
Study: NCT03939533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUTAQUIG
Description: Human normal immunoglobulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUTAQUIG
Description: Human normal immunoglobulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUTAQUIG
Description: Human normal immunoglobulin
Study: NCT02506062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual blood pressure cuff inflation over brachial artery
Description: A manual blood pressure cuff (sphygmomanometer) is used in the study as a tourniquet in order to perform a controlled, consistent level of ischemia (200mmHg/active arm or 60 mmHg/placebo arm).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Manual blood pressure cuff inflation over brachial artery
Description: A manual blood pressure cuff (sphygmomanometer) is used in the study as a tourniquet in order to perform a controlled, consistent level of ischemia (200mmHg/active arm or 60 mmHg/placebo arm).
Study: NCT03429621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone 80 MG
Description: Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery
Study: NCT02527174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Addition of single dose of volasertib intravenously (IV) on Day 4 of treatment protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV daily on Days 1-3 of treatment protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV daily as 24-hour continuous infusion on Day 1-7 of treatment protocol.
Study: NCT02248168

Intervention type: DRUG
Intervention: Pramipexole
Study: NCT04602156

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trocar percutaneous cholecystostomy
Description: Percutaneous cholecystostomy using the one-step Trocar technique under US guidance. An 8Fr Trocar catheter will be inserted percutaneously within the gallbladder under real-time US guidance. The procedure will be performed using an aseptic technique, local anesthesia and intravenous opioid analgesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seldinger percutaneous cholecystostomy
Description: Percutaneous cholecystostomy using the Seldinger technique under US guidance. Following percutaneous puncture of the gallbladder with an 18G needle under real-time US guidance, an 8Fr catheter will be inserted percutaneously over the wire within the gallbladder under real-time US guidance. The procedure will be performed using an aseptic technique, local anesthesia and intravenous opioid analgesia.
Study: NCT00523692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept, methotrexate and depomedrone
Description: Etanercept (50mg weekly; subcutaneous) Methotrexate (7.5-25mg weekly; oral) Depomedrone (up to 120mg; intraarticular / intramuscular)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: depemedrone
Description: depomedrone (up to 120mg im/ia) methotrexate (added after symptoms have been present for 12 weeks)
Study: NCT04570709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative And supportive Care inTervention (PACT)
Description: Using the Adaptive Leadership Framework for Chronic Illness as a guide. The nurse, occupational and physical therapists will meet with the patient and caregiver after the baseline assessment to discuss their Specific, Measurable, Achievable, Relevant, and Time-Bound (SMART) goals. Additionally, the occupational and physical therapists will provide the patient a PACT intervention binder. Regular phone calls or visits from a registered nurse, occupational therapists, and physical therapists for patients and caregivers in the intervention.
Study: NCT02049983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Levita Magnetics Grasper
Study: NCT02675270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonological
Description: This treatment involves picture viewing and word repetition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orthographic
Description: This treatment involves picture viewing, reading, and writing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semantic
Description: This treatment involves learning about the semantic features (meaning) of each trained word.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lexical
Description: This treatment involves learning about the lexical features (letters and sounds) of each trained word.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Untrained
Description: These words are not trained during the treatment phase.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Untrained
Description: These words are not trained during the treatment phase.
Study: NCT04069143

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-BMS-986327
Description: Imaging Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-BMS-986327
Description: Imaging Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-BMS-986327
Description: Imaging Agent